Avinger develops therapeutic devices that incorporate intravascular imaging and the lumivascular approach to treating vascular disease. Its product portfolio includes Ocelot, commercially available since late 2012 to open totally occluded arteries, and Pantheris, a lumivascular atherectomy system that has received CE Mark approval. The company reports its products have helped physicians treat more than 15,000 patients suffering from PAD. Founded in 2007 and based in Redwood City, Calif., Avinger is preparing to begin enrollment in the U.S. VISION trial for Pantheris. Management said it closed a significant funding round with participation from both new and existing investors to support the anticipated clinical trial. The financing was accompanied by three new board additions — James Muzzy, John Delfino and Donald A. Lucas — intended to add strategic management experience. Avinger develops and markets lumivascular interventional devices that integrate light‑based, radiation‑free intravascular imaging into catheters to give physicians live, video‑rate images during arterial treatment. Its commercially available products include the Ocelot family and Lightbox, and it is developing Pantheris™, a next‑generation lumivascular atherectomy device. The company reports its global product portfolio has helped physicians treat more than 13,000 patients with peripheral artery disease. Founded in 2007 by Dr. John B. Simpson and based in Redwood City, Calif., Avinger positions lumivascular technology as a way to improve vascular disease treatment and reduce invasive surgery and amputations. The company used the financing to support continued commercialization of existing products and further development of Pantheris. The article does not disclose revenue figures. Avinger develops catheter-based medical devices that integrate intravascular Optical Coherence Tomography (OCT) to treat peripheral artery disease (PAD). Its product portfolio includes the Ocelot real-time OCT crossing catheter—which is CE marked and commercially available in Europe—and the Wildcat and Kittycat catheters; the company reports its products have helped treat more than 10,000 patients. Avinger is also developing Wolverine, described as the first peripheral atherectomy catheter to incorporate intravascular imaging using OCT. The company plans to invest the new funds to accelerate worldwide sales of existing product lines and to continue R&D and clinical trials for additional intravascular-imaging products. Avinger expects to submit a 510(k) to the FDA for Ocelot later this year. The company highlights the clinical need—PAD impacts 8 to 12 million U.S. adults and contributes to roughly 150,000 leg amputations annually. Avinger was founded in 2007 by Dr. John B. Simpson and is based in Redwood City, Calif. Avinger develops next-generation catheter-based technologies for the treatment of peripheral artery disease (PAD), leveraging intravascular Optical Coherence Tomography (OCT). Its marketed products include the Wildcat and Kittycat catheters and Ocelot, the first real-time OCT crossing catheter. Ocelot received the CE Mark in September 2011 and early EU commercial cases are reported to show remarkable patient outcomes. The company says its global product portfolio has helped physicians treat more than 5,000 patients with PAD. Avinger is focused on developing additional therapeutic devices that incorporate OCT and plans to further U.S. and EU commercialization of Wildcat, Kittycat and Ocelot. It recently closed a financing round to support commercialization and continued technology development. Avinger develops next‑generation catheter-based technologies that merge intravascular imaging and therapeutic capability to treat peripheral artery disease. The company markets the Wildcat and Kittycat guide wire support catheters and is completing development of therapeutic catheters that integrate real‑time OCT imaging. Its pipeline includes the Ocelot catheter, which completed a first‑in‑man feasibility trial in Poland in August 2010, and the Wolverine image‑guided atherectomy catheter. Avinger is completing enrollment in its CONNECT study seeking a more specific FDA indication for the Wildcat device, with enrollment expected to finish in Q1 2011. The company was founded in 2007 and is based in Redwood City, California. A recent $25 million financing will be used to accelerate commercialization and further development of its imaging and therapeutic catheter technologies.

Total raised

$101M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Apr 2013